Copyright Reports & Markets. All rights reserved.

Global Drugs for Central Nervous System Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Drugs for Central Nervous System Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Drugs for Central Nervous System Market Size Growth Rate by Product
      • 1.4.2 OTC
      • 1.4.3 Rx Drugs
    • 1.5 Market by End User
      • 1.5.1 Global Drugs for Central Nervous System Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Retail Pharmacy
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Drugs for Central Nervous System Market Size
      • 2.1.1 Global Drugs for Central Nervous System Revenue 2014-2025
      • 2.1.2 Global Drugs for Central Nervous System Sales 2014-2025
    • 2.2 Drugs for Central Nervous System Growth Rate by Regions
      • 2.2.1 Global Drugs for Central Nervous System Sales by Regions
      • 2.2.2 Global Drugs for Central Nervous System Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Drugs for Central Nervous System Sales by Manufacturers
      • 3.1.1 Drugs for Central Nervous System Sales by Manufacturers
      • 3.1.2 Drugs for Central Nervous System Sales Market Share by Manufacturers
      • 3.1.3 Global Drugs for Central Nervous System Market Concentration Ratio (CR5 and HHI)
    • 3.2 Drugs for Central Nervous System Revenue by Manufacturers
      • 3.2.1 Drugs for Central Nervous System Revenue by Manufacturers (2014-2019)
      • 3.2.2 Drugs for Central Nervous System Revenue Share by Manufacturers (2014-2019)
    • 3.3 Drugs for Central Nervous System Price by Manufacturers
    • 3.4 Drugs for Central Nervous System Manufacturing Base Distribution, Product Types
      • 3.4.1 Drugs for Central Nervous System Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Drugs for Central Nervous System Product Type
      • 3.4.3 Date of International Manufacturers Enter into Drugs for Central Nervous System Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Drugs for Central Nervous System Sales by Product
    • 4.2 Global Drugs for Central Nervous System Revenue by Product
    • 4.3 Drugs for Central Nervous System Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Drugs for Central Nervous System Breakdown Data by End User

    6 North America

    • 6.1 North America Drugs for Central Nervous System by Countries
      • 6.1.1 North America Drugs for Central Nervous System Sales by Countries
      • 6.1.2 North America Drugs for Central Nervous System Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Drugs for Central Nervous System by Product
    • 6.3 North America Drugs for Central Nervous System by End User

    7 Europe

    • 7.1 Europe Drugs for Central Nervous System by Countries
      • 7.1.1 Europe Drugs for Central Nervous System Sales by Countries
      • 7.1.2 Europe Drugs for Central Nervous System Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Drugs for Central Nervous System by Product
    • 7.3 Europe Drugs for Central Nervous System by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Drugs for Central Nervous System by Countries
      • 8.1.1 Asia Pacific Drugs for Central Nervous System Sales by Countries
      • 8.1.2 Asia Pacific Drugs for Central Nervous System Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Drugs for Central Nervous System by Product
    • 8.3 Asia Pacific Drugs for Central Nervous System by End User

    9 Central & South America

    • 9.1 Central & South America Drugs for Central Nervous System by Countries
      • 9.1.1 Central & South America Drugs for Central Nervous System Sales by Countries
      • 9.1.2 Central & South America Drugs for Central Nervous System Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Drugs for Central Nervous System by Product
    • 9.3 Central & South America Drugs for Central Nervous System by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Drugs for Central Nervous System by Countries
      • 10.1.1 Middle East and Africa Drugs for Central Nervous System Sales by Countries
      • 10.1.2 Middle East and Africa Drugs for Central Nervous System Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Drugs for Central Nervous System by Product
    • 10.3 Middle East and Africa Drugs for Central Nervous System by End User

    11 Company Profiles

    • 11.1 Biogen
      • 11.1.1 Biogen Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Biogen Drugs for Central Nervous System Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Biogen Drugs for Central Nervous System Products Offered
      • 11.1.5 Biogen Recent Development
    • 11.2 Pfizer
      • 11.2.1 Pfizer Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Pfizer Drugs for Central Nervous System Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Pfizer Drugs for Central Nervous System Products Offered
      • 11.2.5 Pfizer Recent Development
    • 11.3 Teva
      • 11.3.1 Teva Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Teva Drugs for Central Nervous System Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Teva Drugs for Central Nervous System Products Offered
      • 11.3.5 Teva Recent Development
    • 11.4 Novartis
      • 11.4.1 Novartis Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Novartis Drugs for Central Nervous System Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Novartis Drugs for Central Nervous System Products Offered
      • 11.4.5 Novartis Recent Development
    • 11.5 Johnson & Johnson
      • 11.5.1 Johnson & Johnson Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Johnson & Johnson Drugs for Central Nervous System Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Johnson & Johnson Drugs for Central Nervous System Products Offered
      • 11.5.5 Johnson & Johnson Recent Development
    • 11.6 Eli Lilly
      • 11.6.1 Eli Lilly Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Eli Lilly Drugs for Central Nervous System Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Eli Lilly Drugs for Central Nervous System Products Offered
      • 11.6.5 Eli Lilly Recent Development
    • 11.7 Otsuka
      • 11.7.1 Otsuka Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Otsuka Drugs for Central Nervous System Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Otsuka Drugs for Central Nervous System Products Offered
      • 11.7.5 Otsuka Recent Development
    • 11.8 Merck
      • 11.8.1 Merck Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Merck Drugs for Central Nervous System Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Merck Drugs for Central Nervous System Products Offered
      • 11.8.5 Merck Recent Development
    • 11.9 AstraZeneca
      • 11.9.1 AstraZeneca Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 AstraZeneca Drugs for Central Nervous System Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 AstraZeneca Drugs for Central Nervous System Products Offered
      • 11.9.5 AstraZeneca Recent Development
    • 11.10 Novartis
      • 11.10.1 Novartis Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Novartis Drugs for Central Nervous System Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Novartis Drugs for Central Nervous System Products Offered
      • 11.10.5 Novartis Recent Development
    • 11.11 Shire

    12 Future Forecast

    • 12.1 Drugs for Central Nervous System Market Forecast by Regions
      • 12.1.1 Global Drugs for Central Nervous System Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Drugs for Central Nervous System Revenue Forecast by Regions 2019-2025
    • 12.2 Drugs for Central Nervous System Market Forecast by Product
      • 12.2.1 Global Drugs for Central Nervous System Sales Forecast by Product 2019-2025
      • 12.2.2 Global Drugs for Central Nervous System Revenue Forecast by Product 2019-2025
    • 12.3 Drugs for Central Nervous System Market Forecast by End User
    • 12.4 North America Drugs for Central Nervous System Forecast
    • 12.5 Europe Drugs for Central Nervous System Forecast
    • 12.6 Asia Pacific Drugs for Central Nervous System Forecast
    • 12.7 Central & South America Drugs for Central Nervous System Forecast
    • 12.8 Middle East and Africa Drugs for Central Nervous System Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Drugs for Central Nervous System Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The central nervous system (CNS) is the part of thenervous system consisting of the brain and spinal cord. In this report, we study the drugs for central nervous system disease.
      The global Drugs for Central Nervous System market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Drugs for Central Nervous System market based on company, product type, end user and key regions.

      This report studies the global market size of Drugs for Central Nervous System in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Drugs for Central Nervous System in these regions.
      This research report categorizes the global Drugs for Central Nervous System market by top players/brands, region, type and end user. This report also studies the global Drugs for Central Nervous System market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Biogen
      Pfizer
      Teva
      Novartis
      Johnson & Johnson
      Eli Lilly 
      Otsuka
      Merck
      AstraZeneca
      Novartis
      Shire

      Market size by Product
      OTC
      Rx Drugs
      Market size by End User
      Hospital
      Retail Pharmacy

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Drugs for Central Nervous System market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Drugs for Central Nervous System market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Drugs for Central Nervous System companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Drugs for Central Nervous System submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Drugs for Central Nervous System are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Drugs for Central Nervous System market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now